Allison Nugent
Director of the NIMH Magnetoencephalography (MEG) Core Facility
Data updated
Research Footprint
Allison Nugent appears in 7 tracked papers (2014–2021), most studied alongside Ketamine and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Neuroimaging & Brain Measures.
Most-cited paper: Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine (467 citations).
Frequent co-authors: Carlos Zarate, Evan Ballard and John Evans.
Background & Research
Dr. Allison C. Nugent is the Director of the National Institute of Mental Health (NIMH) Magnetoencephalography (MEG) Core Facility. According to NIMH, she has worked at NIH since 2001, first in Wayne Drevets’ lab and later with Carlos Zarate, applying multimodal neuroimaging to mood and anxiety disorders. Her work spans MEG method development and psychiatric neuroimaging, including ketamine-related studies in depression.
Key Impact
She is a key neuroimaging collaborator on ketamine studies linking rapid antidepressant effects to brain activity changes in depression and healthy participants.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Allison Nugent is associated with.